Novartis AG, of East Hanover, N.J., presented data from its phase III EXPEDITION program at the American Thoracic Society meeting in Denver showing that QVA149 (indacaterol/glycopyrronium), at the 27.5/12.5 mcg dose, demonstrated statistically significant and clinically meaningful improvements in lung function at week 12 compared to its individual components and to placebo in patients with moderate to severe chronic obstructive pulmonary disease.